422 related articles for article (PubMed ID: 10146883)
1. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Barradell LB; McTavish D
Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
[TBL] [Abstract][Full Text] [Related]
2. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
Frampton JE; McTavish D
Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation in gastrointestinal disease.
Jönsson B; Karlsson G
Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
Wilde MI; McTavish D
Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
McTavish D; Buckley MM; Heel RC
Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
7. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
[TBL] [Abstract][Full Text] [Related]
8. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
Fitton A; Wiseman L
Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
Spencer CM; Faulds D
Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the cost-efficacy ratio of omeprazole and ranitidine in the treatment of reflux esophagitis].
Bergmann JF; Hamelin B; Barbier JP
Gastroenterol Clin Biol; 1995 May; 19(5):482-6. PubMed ID: 7589999
[TBL] [Abstract][Full Text] [Related]
13. The clinical utility and safety of omeprazole.
Walan A
Scand J Gastroenterol Suppl; 1989; 166():140-4; discussion 145. PubMed ID: 2574908
[TBL] [Abstract][Full Text] [Related]
14. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
15. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer.
Walan A; Eriksson S
Scand J Gastroenterol Suppl; 1994; 201():91-7. PubMed ID: 8047832
[TBL] [Abstract][Full Text] [Related]
16. Clinical development programme for omeprazole.
Walan A
Digestion; 1990; 47 Suppl 1():54-8; discussion 76. PubMed ID: 2093016
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395
[TBL] [Abstract][Full Text] [Related]
19. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.
Wahlqvist P; Junghard O; Higgins A; Green J
Pharmacoeconomics; 2002; 20(4):279-87. PubMed ID: 11950384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
